Role of the animal model on the pharmacokinetics of equine-derived antivenoms

Aird, 2002, Ophidian envenomation strategies and the role of purines, Toxicon, 40, 335, 10.1016/S0041-0101(01)00232-X Angulo, 1997, Clinical and laboratory alterations in horses during immunization with snake venoms for the production of polyvalent (Crotaline) antivenom, Toxicon, 35, 81, 10.1016/S0041-0101(96)00077-3 Bahloul, 2013, Pulmonary edema following scorpion envenomation: mechanisms, clinical manifestations, diagnosis and treatment, Int. J. Cardiol., 162, 86, 10.1016/j.ijcard.2011.10.013 Battellino, 2003, Assessment of efficacy of bothropic antivenom therapy on microcirculatory effects induced by Bothrops jararaca snake venom, Toxicon, 41, 583, 10.1016/S0041-0101(02)00389-6 Bazin-Redureau, 1998, Interspecies scaling of clearance and volume of distribution of horse antivenom F(ab′)2, Toxicol. Appl. Pharmacol., 150, 295, 10.1006/taap.1997.8363 Bon, 2003, Pharmacokinetics of venom toxins and their modification by antivenom therapy, J. Toxicol., 22, 129 Calderón-Aranda, 1999, Pharmacokinetics of the toxic fraction of Centruroides limpidus limpidus venom in experimentally envenomed rabbits and effects of immunotherapy with specific F(ab′)2, Toxicon, 37, 771, 10.1016/S0041-0101(98)00216-5 Caovilla, 2004, Efficacy of two different doses of antilonomic serum in the resolution of hemorrhagic syndrome resulting from envenoming by Lonomia obliqua caterpillars: a randomized controlled trial, Toxicon, 43, 811, 10.1016/j.toxicon.2004.03.014 1985 El Hafny, 2002, Intraspecific variability and pharmacokinetic characteristics of Androctonus mauretanicus mauretanicus scorpion venom, Toxicon, 40, 1609, 10.1016/S0041-0101(02)00178-2 França, 2003, Envenoming by Bothrops jararaca in Brazil: association between venom antigenaemia and severity at admission to hospital, Trans. R. Soc. Trop. Med. Hyg., 97, 312, 10.1016/S0035-9203(03)90158-1 Gutiérrez, 1998, Neutralization of local tissue damage induced by Bothrops asper (Terciopelo) snake venom, Toxicon, 36, 1529, 10.1016/S0041-0101(98)00145-7 Gutiérrez, 2003, Pharmacokinetic-pharmacodynamic relationships of immunoglobulin therapy for envenomation, Clin. Pharmacikinet., 42, 721, 10.2165/00003088-200342080-00002 Gutiérrez, 2011, Antivenoms for snakebite envenomings, Inflamm. Allergy Drug Targets, 10, 369, 10.2174/187152811797200669 Ismail, 1998, Pharmacokinetics of 125I-labelled IgG, F(ab′)2 and Fab fractions of scorpion and snake antivenins: merits and potential for therapeutic use, Toxicon, 36, 1523, 10.1016/S0041-0101(98)00144-5 Ismail, 1998, Pharmacokinetics of 125I-labelled Walterinnesia aegyptia venom and its specific antivenins: Flash absorption and distribution of the venom and its toxins versus slow absorption and distribution of IgG, F(ab′)2 and Fab of the antivenin, Toxicon, 36, 93, 10.1016/S0041-0101(97)00062-7 Ismail, 1980, Pharmacokinetics of 125I-labelled venom from the scorpion Androctonus amoreuxi, Aud. and Sav, Toxicon, 18, 301, 10.1016/0041-0101(80)90009-4 Jorge, 1995, A randomized “blinded” comparison of two doses of antivenom in the treatment of Bothrops envenoming in São Paulo, Brazil, Trans. R. Soc. Trop. Med. Hyg., 89, 111, 10.1016/0035-9203(95)90678-9 Khattabi, 2011, Classification of clinical consequences of scorpion stings: consensus development, Trans. R. Soc. Trop. Med. Hyg., 105, 364, 10.1016/j.trstmh.2011.03.007 Krifi, 2005, Pharmacokinetic studies of scorpion venom before and after antivenom immunotherapy, Toxicon, 45, 187, 10.1016/j.toxicon.2004.10.007 Lalloo, 2003, Snake antivenoms, J. Toxicol. Clin. Toxicol., 41, 277, 10.1081/CLT-120021113 León, 2001, Comparison between IgG and F(ab′)2 polyvalent antivenoms: neutralization of systemic effects induced by Bothrops asper venom in mice, extravasation to muscle tissue, and potential for induction of adverse reactions, Toxicon, 39, 793, 10.1016/S0041-0101(00)00209-9 Lobo, 2004, Antibody pharmacokinetics and pharmacodynamics, J. Pharm. Sci., 93, 2645, 10.1002/jps.20178 Nisani, 2011, Defensive stinging by Parabuthus transvaalicus scorpions: risk assessment and antivenom metering, Anim. Behav., 81, 627, 10.1016/j.anbehav.2010.12.010 Offerman, 2011, The treatment of black widow spider envenomation with antivenin Latrodectus mactans: a case series, Perm. J., 15, 76, 10.7812/TPP/10-136 Otero-Patiño, 2012, Comparative study on the efficacy and safety of two polyvalent, caprylic acid fractionated IgG and F(ab′)2 antivenoms, in Bothrops asper bites in Colombia, Toxicon, 59, 344, 10.1016/j.toxicon.2011.11.017 Pauli, 2006, The efficacy of antivenom in loxoscelism treatment, Toxicon, 48, 123, 10.1016/j.toxicon.2006.05.005 Pépin-Covatta, 1996, Immunoreactivity and pharmacokinetics of horse anti-scorpion venom F(ab′)2-scorpion venom interactions, Toxicol. Appl. Pharmacol., 141, 272, 10.1016/S0041-008X(96)80033-0 Pinto, 2010, Lonomia obliqua venom: in vivo effects and molecular aspects associated with the hemorrhagic syndrome, Toxicon, 56, 1103, 10.1016/j.toxicon.2010.01.013 Quesada, 2006, Pharmacokinetics of whole IgG equine antivenom: comparison between normal and envenomed rabbits, Toxicon, 48, 255, 10.1016/j.toxicon.2006.05.010 Rivière, 1997, Effect of antivenom on venom pharmacokinetics in experimentally envenomed rabbits: towards an optimization of antivenom therapy, J. Pharmacol. Exp. Ther., 281, 1 Rojas, 1994, Caprylic acid fractionation of hyperimmune horse plasma: description of a simple procedure for antivenom production, Toxicon, 32, 351, 10.1016/0041-0101(94)90087-6 Scherrmann, 1994, Antibody treatment of toxin poisoning: recent advances, Clin. Toxicol., 32, 363, 10.3109/15563659409011037 Sellahewa, 1995, Efficacy of antivenom in the treatment of severe local envenomation by the hump-nosed viper (Hypnale hypnale), Am. J. Trop. Med. Hyg., 53, 260, 10.4269/ajtmh.1995.53.260 Selvanayagam, 1999, ELISA for the detection of venoms from four medically important snakes of India, Toxicon, 37, 757, 10.1016/S0041-0101(98)00215-3 Sevcik, 2004, Modelling Tityus scorpion venom and antivenom pharmacokinetics. Evidence of active immunoglobulin G's F(ab′)2 extrusion mechanism from blood to tissues, Toxicon, 44, 731, 10.1016/j.toxicon.2004.07.032 Sevcik, 2007, Initial volume of a drug before it reaches the volume of distribution: pharmacokinetics of F(ab′)2 antivenoms and other drugs, Toxicon, 50, 653, 10.1016/j.toxicon.2007.05.011 Thomas, 1998, Tolérance et efficacitté d'un fragment F(ab′)2 antivenimeux (équin) spécifique administré par voie intraveineuse dans le traitement des morsures de serpent (Bothrops lanceolatus) en Martinique, Réan Urg., 7, 381, 10.1016/S1164-6756(98)80004-2 Vázquez, 2005, Pharmacokinetics of a F(ab′)2 scorpion antivenom in healthy human volunteers, Toxicon, 46, 797, 10.1016/j.toxicon.2005.08.010 Vázquez, 2010, Pharmacokinetics of a F(ab′)2 scorpion antivenom administered intramuscularly in healthy human volunteers, Int. Immunopharmacol., 10, 1318, 10.1016/j.intimp.2010.08.018 Vázquez, 2010, Pharmacokinetics in rabbits and anti-sphingomyelinase D neutralizing power of Fab, F(ab′)2, IgG and IgG(T) fragments from hyper immune equine plasma, Int. Immunopharmacol., 10, 447, 10.1016/j.intimp.2010.01.005 Visser, 2008, Failure of a new antivenom to treat Echis ocellatus snake bite in rural Ghana: the importance of quality surveillance, Trans. R. Soc. Trop. Med. Hyg., 102, 445, 10.1016/j.trstmh.2007.11.006 2010 Wigger, 2002, The venom optimization hypothesis: a spider injects large venom quantities only into difficult prey types, Toxicon, 40, 749, 10.1016/S0041-0101(01)00277-X